JP2019537613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537613A5 JP2019537613A5 JP2019526465A JP2019526465A JP2019537613A5 JP 2019537613 A5 JP2019537613 A5 JP 2019537613A5 JP 2019526465 A JP2019526465 A JP 2019526465A JP 2019526465 A JP2019526465 A JP 2019526465A JP 2019537613 A5 JP2019537613 A5 JP 2019537613A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- tautomer
- compound according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 2
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 238000003419 tautomerization reaction Methods 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611012431 | 2016-11-17 | ||
| CN201611012431.5 | 2016-11-17 | ||
| PCT/CN2017/111634 WO2018090973A1 (zh) | 2016-11-17 | 2017-11-17 | Fgfr4抑制剂及其制备方法和应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019537613A JP2019537613A (ja) | 2019-12-26 |
| JP2019537613A5 true JP2019537613A5 (cg-RX-API-DMAC7.html) | 2020-10-15 |
| JP7063899B2 JP7063899B2 (ja) | 2022-05-09 |
Family
ID=62145242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526465A Active JP7063899B2 (ja) | 2016-11-17 | 2017-11-17 | Ｆｇｆｒ４阻害剤、その製造方法及び使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11008292B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3543227B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7063899B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102249632B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109952290B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017359819B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3043948C (cg-RX-API-DMAC7.html) |
| IL (1) | IL266659B (cg-RX-API-DMAC7.html) |
| MX (1) | MX389403B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ754218A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018090973A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201903845B (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018361264B2 (en) * | 2017-11-01 | 2021-04-01 | Guangdong Xianqiang Pharmaceutical Co., Ltd | Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101003514A (zh) | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
| CN102731485B (zh) | 2011-04-02 | 2016-06-15 | 齐鲁制药有限公司 | 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途 |
| BR112015000653A2 (pt) | 2012-07-11 | 2019-11-05 | Blueprint Medicines Corp | compostos inibidores do receptor de fator de crescimento de fibroblasto, sua composição farmacêutica e seus usos |
| WO2014139145A1 (en) | 2013-03-15 | 2014-09-18 | Hutchison Medipharma Limited | Novel pyrimidine and pyridine compounds and usage thereof |
| SG11201602069WA (en) | 2013-10-18 | 2016-04-28 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| WO2016115412A1 (en) | 2015-01-18 | 2016-07-21 | Newave Pharmaceutical Llc | Dual-warhead covalent inhibitors of fgfr-4 |
| WO2016164703A1 (en) | 2015-04-09 | 2016-10-13 | Eisai R & D Management Co., Ltd. | Fgfr4 inhibitors |
| CN107660200B (zh) | 2015-04-14 | 2022-01-11 | 卫材R&D管理有限公司 | 结晶fgfr4抑制剂化合物和其用途 |
| AU2018361264B2 (en) * | 2017-11-01 | 2021-04-01 | Guangdong Xianqiang Pharmaceutical Co., Ltd | Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof |
-
2017
- 2017-11-17 US US16/461,373 patent/US11008292B2/en active Active
- 2017-11-17 KR KR1020197016780A patent/KR102249632B1/ko active Active
- 2017-11-17 EP EP17871196.6A patent/EP3543227B1/en active Active
- 2017-11-17 CA CA3043948A patent/CA3043948C/en active Active
- 2017-11-17 MX MX2019005723A patent/MX389403B/es unknown
- 2017-11-17 JP JP2019526465A patent/JP7063899B2/ja active Active
- 2017-11-17 NZ NZ754218A patent/NZ754218A/en active IP Right Revival
- 2017-11-17 CN CN201780070537.7A patent/CN109952290B/zh active Active
- 2017-11-17 AU AU2017359819A patent/AU2017359819B2/en active Active
- 2017-11-17 WO PCT/CN2017/111634 patent/WO2018090973A1/zh not_active Ceased
-
2019
- 2019-05-15 IL IL266659A patent/IL266659B/en unknown
- 2019-06-13 ZA ZA2019/03845A patent/ZA201903845B/en unknown